Collegium Pharmaceutical Priced, Nasdaq: COLL

Developing an abuse-deterrent oral formulation of oxycodone for pain.

Industry: Health Care

Latest Trade: $11.49 +0.19 (+1.7%)

First Day Return: +2.4%

Return from IPO: -5.8%

Industry: Health Care

We are a specialty pharmaceutical company developing and planning to commercialize next-generation abuse-deterrent products that incorporate our patented DETERx platform technology for the treatment of chronic pain and other diseases. Our lead product candidate, Xtampza, is an abuse-deterrent, extended-release, oral formulation of oxycodone, a widely prescribed opioid medication. On November 6, 2015, the FDA granted tentative approval to the NDA for Xtampza for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate. The FDA granted tentative approval because Xtampza met the required quality, safety and efficacy standards for approval but remains subject to an automatic stay of up to 30 months as a result of patent litigation filed by Purdue Pharma in March 2015. The FDA may grant final regulatory approval upon the earliest to occur of expiration of the automatic stay, the court invalidating Purdue's patents or issuing an opinion of non-infringement, and expiration of Purdue's listed patents.
more less
IPO News for Collegium Pharmaceutical
more
IPO Data
IPO File Date 04/02/2015
Offer Price $12.00
Price Range $12.00 - $14.00
Offer Shares (mm) 5.8
Deal Size ($mm) $70
IPO Data
IPO Date 05/06/2015
Offer Price $12.00
Price Range $12.00 - $14.00
Offer Shares (mm) 5.8
Deal Size ($mm) $70
Underwriters
more
Company Data
Headquarters Canton, MA
Founded 2002
Employees 24
Website www.collegiumpharma.com